Second primary malignancies in blastic plasmacytoid dendritic cell neoplasm: A national database study

Ramachandran, Vignesh; Park, Katherine E.; Loya, Asad; Duvic, Madeleine

doi:10.1016/j.jaad.2020.03.101

Cited by 4 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these studies, only Julia et al reported six cases of BPDCN with a history of CML in all 90 cases [ 16 ]. Although BPDCN is a lethal disease, some cases have been reported after diagnosis (Table 3 ) [ 17 - 19 ]. Ramachandran et al investigated the risk of secondary primary malignancies (SPMs) in patients with initial BPDCN using the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…Although BPDCN is a lethal disease, some cases have been reported after diagnosis (Table 3 ) [ 17 - 19 ]. Ramachandran et al investigated the risk of secondary primary malignancies (SPMs) in patients with initial BPDCN using the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database [ 19 ]. In 932 patients with BPDCN, SPMs occurred in 43 patients and hematologic malignancies in 12 patients; however, they did not include CML patients.…”

Section: Discussionmentioning

confidence: 99%

“…[17][18][19]. Ramachandran et al investigated the risk of secondary primary malignancies (SPMs) in patients with initial BPDCN using the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database[19].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Blastic Plasmacytoid Dendritic Cell Neoplasm Developed in Chronic Myeloid Leukemia in Molecular Remission During a Four-Year Treatment-Free Interval After Six Years of Dasatinib Treatment

Suzuki,

Takeshita,

Hirai

et al. 2024

Cureus

View full text Add to dashboard Cite

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy affecting multiple sites, most commonly the skin. About 10-20% of BPDCN cases are accompanied by hematological neoplasms. A 71-year-old male was diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP) 11 years prior (at 60 years of age), and dasatinib treatment was initiated. A major molecular response (MMR) was achieved 18 months after diagnosis, and the molecular response (MR) 4.0 lasted beyond 36 months. Due to pancytopenia, dasatinib was discontinued at 74 months, but the CML-CP remained undetectable. One hundred and twenty-two months after the diagnosis, the patient presented with cutaneous lesions on the forehead and abdomen. Immunological and histological analyses of the skin biopsy showed infiltration of atypical cells from the deep epidermis to the entire dermis, expressing clusters of differentiation (CD) 4, CD56, and CD123 without any other markers. The same cells were observed in bone marrow samples. BPDCN was diagnosed, followed by chemotherapy and possibly autologous or allogeneic hematopoietic stem cell transplantation (HSCT). To the best of our knowledge, this is the first case report of the development of BPDCN in a patient with CML in molecular remission. Further studies are required to clarify the pathogenesis of BPDCN in patients with hematological malignancies in remission.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Blastic Plasmacytoid Dendritic Cell Neoplasm Developed in Chronic Myeloid Leukemia in Molecular Remission During a Four-Year Treatment-Free Interval After Six Years of Dasatinib Treatment

Suzuki,

Takeshita,

Hirai

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…There are still few data, but it may constitute an argument in cases overlapping with BPDCN. It should be noted that BPDCN may also be associated with myeloid neoplasms, either concomitantly or sequentially [ 123 , 124 ]. The associated neoplasm is usually CMML [ 125 , 126 , 127 ], but it can also be a MDS [ 128 , 129 , 130 , 131 ].…”

Section: Discussionmentioning

confidence: 99%

Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells

Renosi

Callanan

Lefebvre

2022

Cancers

View full text Add to dashboard Cite

Plasmacytoid Dendritic Cells (pDC) are type I interferon (IFN)-producing cells that play a key role in immune responses. Two major types of neoplastic counterparts for pDC are now discriminated: Blastic pDC Neoplasm (BPDCN) and Mature pDC Proliferation (MPDCP), associated with myeloid neoplasm. Two types of MPDCP are now better described: Chronic MyeloMonocytic Leukemia with pDC expansion (pDC-CMML) and Acute Myeloid Leukemia with pDC expansion (pDC-AML). Differential diagnosis between pDC-AML and BPDCN is particularly challenging, and genomic features can help for diagnosis. Here, we systematically review the cytogenetic, molecular, and transcriptional characteristics of BPDCN and pDC-AML. BPDCN are characterized by frequent complex karyotypes with recurrent MYB/MYC rearrangements as well as recurrent deletions involving ETV6, IKZF1, RB1, and TP53 loci. Epigenetic and splicing pathways are also particularly mutated, while original processes are dysregulated, such as NF-kB, TCF4, BCL2, and IFN pathways; neutrophil-specific receptors; and cholinergic signaling. In contrast, cytogenetic abnormalities are limited in pDC-AML and are quite similar to other AML. Interestingly, RUNX1 is the most frequently mutated gene (70% of cases). These typical genomic features are of potential interest for diagnosis, and also from a prognostic or therapeutic perspective.

show abstract

“…In 2008, the World Health Organization clarified the cell of origin and it is now classified as a distinct clinical disease of malignant proliferation of a contingent blastic plasmacytoid dendritic cell [1,3]. It is considered a subtype of acute myeloid leukemia and related neoplasms and represents approximately 0.8% of primary cutaneous lymphomas [3,4]. Phenotypically, it is characterized by the expression of CD4, CD56, CD123, blood dendritic cell antigen (BDCA)2, T-Cell leukemia/lymphoma (TCL)1, and Bcell lymphoma/leukemia (BCL)11A [3].…”

Section: Case Discussionmentioning

confidence: 99%

Blastic plasmacytoid dendritic cell neoplasm presenting as violaceous forehead plaque

Morrison¹,

Hopkins²,

Knapp³

et al. 2022

DOJ

View full text Add to dashboard Cite

Second primary malignancies in blastic plasmacytoid dendritic cell neoplasm: A national database study

Cited by 4 publications

References 2 publications

Blastic Plasmacytoid Dendritic Cell Neoplasm Developed in Chronic Myeloid Leukemia in Molecular Remission During a Four-Year Treatment-Free Interval After Six Years of Dasatinib Treatment

Blastic Plasmacytoid Dendritic Cell Neoplasm Developed in Chronic Myeloid Leukemia in Molecular Remission During a Four-Year Treatment-Free Interval After Six Years of Dasatinib Treatment

Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells

Blastic plasmacytoid dendritic cell neoplasm presenting as violaceous forehead plaque

Contact Info

Product

Resources

About